Screener
MoonLake Immunotherapeutics MLTX EPS (Diluted)
Discontinued — last reported Q1 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Numerator | ||
| Net loss attributable to controlling interests shareholders | $(69,707) | $(39,944) |
| Denominator | ||
| Total weighted average number of outstanding shares | 71,273,650 | 63,233,788 |
| Net loss per share – basic and diluted | $(0.98) | $(0.63) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's EPS (diluted)?
- MoonLake Immunotherapeutics (MLTX) reported EPS (diluted) of -$0.98 in Q1 2026.
- How has MoonLake Immunotherapeutics's EPS (diluted) changed year-over-year?
- MoonLake Immunotherapeutics's EPS (diluted) decreased by 55.6% year-over-year, from -$0.63 to -$0.98.
- What is the long-term trend for MoonLake Immunotherapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's EPS (diluted) has grown at a -27.0% compound annual growth rate (CAGR), from -$12.37 to -$3.52.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about MoonLake Immunotherapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude